Resource Library

Cost-Effectiveness Analysis of 3 Months of Weekly Rifapentine and Isoniazid Compared to Isoniazid Monotherapy in a Canadian Arctic Setting

2021

Pease, C., Alvarez, G., Mallick, R., Patterson, M., Finn, S., Habis, Y., Schwartzman, K., Kilabuk, E., Mulpuru, S., & Zwerling, A.

BMJ Group

Description

The authors compared the cost effectiveness of a once weekly dose of rifapentine and isoniazid for 12 weeks (3HP) regimen to 9 months of twice weekly isoniazid (9H) given by directly observed therapy in the treatment of latent TB infection in Iqaluit, Nunavut. The authors found that the 3HP regimen had superior effectiveness, with lower costs, slighly better health outcomes, and fewer TB cases and deaths. The primary driver of cost-effectiveness for the 3HP regimen was lower number of DOT visits due to shorter regimen.

Link to Resource

Cost-Effectiveness Analysis of 3 Months of Weekly Rifapentine and Isoniazid Compared to Isoniazid Monotherapy in a Canadian Arctic Setting.

Pease, C., Alvarez, G., Mallick, R., Patterson, M., Finn, S., Habis, Y., Schwartzman, K., Kilabuk, E., Mulpuru, S., & Zwerling, A. (2021). Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting. BMJ Open, 11, e047514. doi: 10.1136/bmjopen-2020-047514